India Women’s Health Therapeutics Market Assessment, By Drug [ACTONEL, FORTEO, Mirena, NuvaRing, Premarin, Prolia, Others], By Indication [Hormonal Infertility, Cancer, Contraceptives, Postmenopausal Osteoporosis, Endometriosis and Uterine Fibroids, Menopause, Polycystic Ovary Syndrome, Others], By Age-group [Below 18, 18 to 45, Above 45], By End-user [Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others], By Region, Opportunities and Forecast, FY2018-FY2032F

India women’s health therapeutics market is projected to witness a CAGR of 13.10% during the forecast period FY2025-FY2032, growing from USD 1.98 billion in FY2024 to USD 5.30 billion in FY2032. India market for women’s health therapeutics has grown significantly because of recent advancements in technologies and the growing demand for efficient solutions. One of the primary factors propelling market expansions in the country is most of the population's declining reproductive health owing to the sedentary lifestyles and shifting environmental conditions.

Report Attribute	Details
Base Year of the Analysis	FY2024
Historical Period	FY2018-FY2023
Forecast Period	FY2025-FY2032
Projected Growth Rate	CAGR of 13.10% between FY2025 and FY2032
Revenue Forecast in FY2032	USD 5.30 billion

In June 2024, Orchid Pharma partnered with Cipla to launch Cefepime-Enmetazobactam, a breakthrough antibiotic combination approved for treating complicated Urinary Tract infections (cUTI), Ventilator-Associated Pneumonia (VAP), and Hospital-Acquired Pneumonia (HAP). This collaboration ensured widespread distribution of this treatment across India. In addition, the partnership combined Orchid's drug development capabilities with Cipla's distribution network, ensuring that this life-saving medication reaches healthcare providers efficiently.

Government Initiatives Fueling the Market Growth

Support from the government is crucial for the growth of women’s health therapeutics market in India. Women's healthcare access, affordability, and awareness are receiving attention at the policy level, and many programs have been initiated to aid this. For example, Pradhan Mantri Surakshit Matritva Abhiyan (PMSMA) guarantees free prenatal checkups, while the adolescent health program focuses on the RKSK. Furthermore, the Ayushman Bharat Scheme enables fast financial aid to women facing costly procedures, including cancer treatments. Other regulations, such as drug price limits set by the NPPA, increase affordability of important drugs and medicines. There are also efforts to increase self-sufficiency in pharmaceuticals through the Production-Linked Incentive (PLI) Scheme, which promotes local businesses instead of foreign ones. The surge in funding directed toward women’s health studies, the opening of new Janaushadhi Kendras, and changes in policy that favor menstrual and reproductive health care amplify the sales potential further. Such policy support guarantees usage of women healthcare services in India for both urban and rural areas, which is likely to bring forth many solutions for women's health issues. For instance, launched in Odisha, this universal health coverage program provides annual health coverage of USD 5,726 per family and USD 8,016 for female members. The scheme aims to enhance healthcare accessibility, particularly benefiting women in the state

Scientific Innovations Boosting Market Growth

Scientific research is a key driver in Women health therapeutics, resulting in sophisticated treatments, improved diagnostic technology, and targeted therapies. There has been an increase in government and private funding leading to faster paced research in endometriosis, polycystic ovarian syndrome (PCOS), infertility, and menopausal research. The rise of precision medicine and biotechnology has facilitated the development of personalized hormonal treatment for reproductive disorders, as well as non-invasive diagnostic tools. There has also been considerable progress in stem cell therapies and gene editing alongside drug delivery systems using nanotechnology for improving women’s health in India. The Indian Council of Medical Research (ICMR) is collaborating with private pharma companies on clinical trials of new cancer therapies, fertility drugs, and HPV vaccines. These investments in R&D enable the advancement of woman healthcare by improving the efficacy, affordability, and accessibility of these treatments. For example, In December 2024, Novo Nordisk India advocated for an expedited launch of its weight-loss drug for women, called Wegovy, to compete with Eli Lilly’s anticipated introduction of Mounjaro in 2025. Both drugs are GLP-1 receptor agonists, highly sought after for weight management.

Rising Incidence of Cancer Fueling the Market Growth

The increasing occurrence of cancer, particularly among women in India, is one of the major factors for the growth of the women’s health therapeutics market. There is an increase in breast, cervical, ovarian, and endometrial cancers due to changes in lifestyle, genetic factors, and diagnosis at a later stage. As per the National Cancer Registry Programme (NCRP), the number of breast cancer cases in India has increased twofold over the past ten years, making it the most prevalent cancer among women. The surge in cases of HPV-induced cervical cancer recently prompted the government to implement vaccination drives across the country which stimulated demand for HPV vaccines. There is a growing pharmaceutical investment in oncology drugs due to the advances in targeted therapies, immunotherapy, and hormone therapy. The introduction of awareness programs on cancer, early detection, and increased access to cancer treatment through Ayushman Bharat is causing a rise in the need for novel and cost-effective women-centric cancer therapeutics. This growing burden of disease amplifies the demand for greater research, improved diagnostic tools, and more sophisticated treatment options.  According to Observer Research Foundation, the number of cases of breast cancer increased steadily from 200,218 in 2019 to 221,579 in 2023; at the same time, the number of deaths from the disease increased from 74,481 to 82,429 in India. Even while incidence is far higher than fatality, mortality rates have been steadily rising, which suggests problems with early detection, access to treatment, and efficient management.

Download Free Sample Report

Future Market Scenario (FY2025 – FY2032F)

Many factors claim the growth of India women’s health therapeutics market. Technological advancements give faster and more accurate results leading us to early diagnosis. Opportunity also lies in the increasing number of fertility concerns that the population is facing today. Promising initiatives of our government that provide healthcare infrastructure, funds to carry on research and development on a large scale, and a reliable distribution channel that ensures the solution reaches everyone is testimonial. For instance, from primary healthcare facilities to sophisticated tertiary care hospitals, India currently has a vast healthcare infrastructure. One of the biggest healthcare systems in the world is expected to grow because of increased public and private sector investment. To increase access to high-quality healthcare for a larger portion of the population, developers are currently collaborating with healthcare providers to build cutting-edge facilities in tier 2 and tier 3 cities as well as metropolitan areas.

Report Scope

“India Women’s Health Therapeutics Market Assessment, Opportunities, and Forecast, FY2018-FY2032F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of the India women’s health therapeutics market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between FY2025 and FY2032. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Report Attribute	Details
Segments Covered	Drug, Indication, Age-group, End-user
Regions Covered	North, South, East, West and Central
Key Companies Profile	Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson Services, Inc., AstraZeneca plc
Customization Scope	15% free report customization with purchase
Pricing and Purchase Options	Avail the customized purchase options to fulfill your precise research needs
Delivery Format	PDF and Excel through email (subject to the license purchased)

In the report, the India women’s health therapeutics market has been segmented into the following categories: 

• By Drug
  • ACTONEL
  • FORTEO
  • Mirena
  • NuvaRing
  • Premarin
  • Prolia
  • Others
• By Indication
  • Hormonal Infertility
  • Cancer
    • Cervical Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Ovarian Cancer
    • Others
  • Contraceptives
  • Postmenopausal Osteoporosis
  • Endometriosis and Uterine Fibroids
  • Menopause
  • Polycystic Ovary Syndrome (PCOS)
  • Others
• By Age-group
  • Below 18
  • 18 to 45
  • Above 45
• By End-user
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
• By Region
  • North
  • South
  • East
  • West and Central

Key Players Landscape and Outlook

Key players in the women’s health therapeutics industry utilize strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing big-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For instance, Pradhan Mantri Bharatiya Janaushadhi Pariyojana (PMBJP) is an initiative which has expanded significantly, offering over 2,000 types of generic drugs and more than 300 surgical products by 2024. Notably, the scheme includes the “Janaushadhi Suvidha Oxy-Biodegradable Sanitary Napkin,” providing affordable sanitary products to women across the country.

Key Players Operating in India Women’s Health Therapeutics Market are:

• Merck & Co., Inc.
• Pfizer Inc.
• GlaxoSmithKline plc
• Hoffmann-La Roche Ltd
• AbbVie Inc.
• Amgen Inc.
• Novartis AG
• Eli Lilly and Company
• Johnson & Johnson Services, Inc.
• AstraZeneca plc

If you can't find what you're searching for or have any custom requirements for India women’s health therapeutics market, you may approach our team at info@marketsandata.com